[go: up one dir, main page]

AU2001248171A1 - Chlamydia antigens and corresponding dna fragments and uses thereof - Google Patents

Chlamydia antigens and corresponding dna fragments and uses thereof

Info

Publication number
AU2001248171A1
AU2001248171A1 AU2001248171A AU4817101A AU2001248171A1 AU 2001248171 A1 AU2001248171 A1 AU 2001248171A1 AU 2001248171 A AU2001248171 A AU 2001248171A AU 4817101 A AU4817101 A AU 4817101A AU 2001248171 A1 AU2001248171 A1 AU 2001248171A1
Authority
AU
Australia
Prior art keywords
dna fragments
corresponding dna
chlamydia antigens
chlamydia
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001248171A
Inventor
Pamela Dunn
Andrew D. Murdin
Raymond P Oomen
Joe Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur Ltd, Aventis Pasteur SA filed Critical Aventis Pasteur Ltd
Publication of AU2001248171A1 publication Critical patent/AU2001248171A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001248171A 2000-04-04 2001-04-04 Chlamydia antigens and corresponding dna fragments and uses thereof Abandoned AU2001248171A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19446400P 2000-04-04 2000-04-04
US60/194,464 2000-04-04
PCT/CA2001/000455 WO2001074863A2 (en) 2000-04-04 2001-04-04 Chlamydia antigens and corresponding dna fragments and uses thereof

Publications (1)

Publication Number Publication Date
AU2001248171A1 true AU2001248171A1 (en) 2001-10-15

Family

ID=22717698

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001248171A Abandoned AU2001248171A1 (en) 2000-04-04 2001-04-04 Chlamydia antigens and corresponding dna fragments and uses thereof

Country Status (3)

Country Link
US (2) US20020071831A1 (en)
AU (1) AU2001248171A1 (en)
WO (1) WO2001074863A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3790900A (en) * 1998-12-01 2000-06-19 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
MXPA01005615A (en) * 1998-12-04 2004-08-19 Univ Manitoba Two-step immunization procedure against chlamydia.
JP2003512017A (en) * 1998-12-23 2003-04-02 アベンティス、パストゥール、リミテッド Chlamydia antigens and corresponding DNA fragments and uses thereof
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
DE60041042D1 (en) 1999-03-12 2009-01-22 Aventis Pasteur CHLAMYDIA ANTIGENES AND THEIR CORRESPONDING DNA FRAGMENTS AND USES THEREOF
DE60036698T2 (en) 1999-05-03 2008-07-24 Sanofi Pasteur Ltd., Toronto CHLAMYDIA ANTIGENES AND CORRESPONDING DNA FRAGMENTS AND ITS USES
WO2001021804A1 (en) * 1999-09-20 2001-03-29 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
EP1240331B1 (en) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020082402A1 (en) * 2000-04-04 2002-06-27 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
US20040254130A1 (en) * 2000-05-08 2004-12-16 Murdin Andrew D Chlamydia antigens and corresponding dna fragments and uses thereof
US20080112965A1 (en) * 2001-10-01 2008-05-15 Aventis Pasteur Limited Chlamydia OMP antigen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
JP2002536958A (en) * 1997-11-21 2002-11-05 ジェンセット Chlamydiapneumoniae genomic sequences and polypeptides, fragments thereof, and their use especially for the diagnosis, prevention and treatment of infectious diseases
PT1032674E (en) 1997-11-21 2007-03-30 Serono Genetics Inst Sa (chlamydia pneumoniae) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
US6403101B1 (en) 1998-10-28 2002-06-11 Connaught Laboratories Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
DE60139690D1 (en) * 2000-07-03 2009-10-08 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE

Also Published As

Publication number Publication date
WO2001074863A2 (en) 2001-10-11
US20020071831A1 (en) 2002-06-13
US20030206921A1 (en) 2003-11-06
US7081245B2 (en) 2006-07-25
WO2001074863A3 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
AU7398200A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
EP1247815A3 (en) Modified oligonucleotides and uses thereof
AU2001287430A1 (en) Moraxella polypeptides and corresponding dna fragments and uses thereof
AU2001278061A1 (en) Triphosphate oligonucleotide modification reagents and uses thereof
AU2001248176A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248172A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2138501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001248171A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248177A1 (en) Chlamydia myosin heavy chain homolog as antigen, corresponding dna fragments and uses thereof
AU2001248178A1 (en) Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof
AU2138601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
EP2088197B8 (en) Haemophilus influenzae antigens and corresponding DNA fragments
AU2001274566A1 (en) Novel protein and dna thereof
AU2001295582A1 (en) Tumour-related antigens
AU2002216863A1 (en) Streptococcus pyogenes antigens and corresponding DNA fragments
AU2001285155A1 (en) Polymorphic dna fragments and uses thereof
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU1375501A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU7398400A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU5668500A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU7398600A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU1375701A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU7398700A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU7398300A (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU1375601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof